Nexalin Technology Inc. (NXL): Price and Financial Metrics

Nexalin Technology Inc. (NXL): $1.23

0.08 (-6.11%)

POWR Rating

Component Grades








NXL Price/Volume Stats

Current price $1.23 52-week high $3.40
Prev. close $1.31 52-week low $0.25
Day low $1.15 Volume 50,200
Day high $1.39 Avg. volume 543,113
50-day MA $1.38 Dividend yield N/A
200-day MA $0.65 Market Cap 9.15M

NXL Stock Price Chart Interactive Chart >

NXL Latest News Stream

Event/Time News Detail
Loading, please wait...

NXL Latest Social Stream

Loading social stream, please wait...

View Full NXL Social Stream

Latest NXL News From Around the Web

Below are the latest news stories about NEXALIN TECHNOLOGY INC that investors may wish to consider to help them evaluate NXL as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!

William White on InvestorPlace | December 12, 2023

Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter

HOUSTON, TEXAS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the formation of a Military & Government Advisory Board ( “Advisory Board”) to support its non-invasive, frequency-based, deep-brain stimulation devices within U.S. government agencies. Spearheaded by David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy and leading government affairs veteran, the Advisory Board will work closely with

Yahoo | October 25, 2023

Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures

Study reveals that Nexalin’s non-invasive, deep frequency stimulation medical device can directly stimulate the deep intracranial nuclei, an area of the brain frequently associated with trauma and mental health diseaseHOUSTON, TX, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a research article titled, “Evidence of a large current of transcranial alternating current stimulation directly to deep brai

Yahoo | October 16, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning!

William White on InvestorPlace | October 2, 2023

Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

New migraine data builds on prior clinical studies in depression Migraine trial results Migraine trial results Depression trial results Depression trial results HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in p

Yahoo | August 7, 2023

Read More 'NXL' Stories Here

NXL Price Returns

1-mo -13.99%
3-mo 272.73%
6-mo 252.94%
1-year 55.72%
3-year N/A
5-year N/A
YTD 203.85%
2023 -45.95%
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!